CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup
- PMID: 19249009
- PMCID: PMC2668007
- DOI: 10.1016/j.ajhg.2009.02.003
CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup
Abstract
Huntington disease (HD) is an autosomal-dominant disorder that results from >or=36 CAG repeats in the HD gene (HTT). Approximately 10% of patients inherit a chromosome that underwent CAG expansion from an unaffected parent with <36 CAG repeats. This study is a comprehensive analysis of genetic diversity in HTT and reveals that HD patients of European origin (n = 65) have a significant enrichment (95%) of a specific set of 22 tagging single nucleotide polymorphisms (SNPs) that constitute a single haplogroup. The disease association of many SNPs is much stronger than any previously reported polymorphism and was confirmed in a replication cohort (n = 203). Importantly, the same haplogroup is also significantly enriched (83%) in individuals with 27-35 CAG repeats (intermediate alleles, n = 66), who are unaffected by the disease, but have increased CAG tract sizes relative to the general population (n = 116). These data support a stepwise model for CAG expansion into the affected range (>or=36 CAG) and identifies specific haplogroup variants in the general population associated with this instability. The specific variants at risk for CAG expansion are not present in the general population in China, Japan, and Nigeria where the prevalence of HD is much lower. The current data argue that cis-elements have a major predisposing influence on CAG instability in HTT. The strong association between specific SNP alleles and CAG expansion also provides an opportunity of personalized therapeutics in HD where the clinical development of only a small number of allele-specific targets may be sufficient to treat up to 88% of the HD patient population.
Figures







Comment in
-
Haplotype background, repeat length evolution, and Huntington's disease.Am J Hum Genet. 2009 Dec;85(6):939-42. doi: 10.1016/j.ajhg.2009.11.002. Am J Hum Genet. 2009. PMID: 20004772 Free PMC article. No abstract available.
Similar articles
-
HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia.Eur J Hum Genet. 2011 May;19(5):561-6. doi: 10.1038/ejhg.2010.229. Epub 2011 Jan 19. Eur J Hum Genet. 2011. PMID: 21248742 Free PMC article.
-
Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes.Eur J Hum Genet. 2013 Oct;21(10):1120-7. doi: 10.1038/ejhg.2013.2. Epub 2013 Mar 6. Eur J Hum Genet. 2013. PMID: 23463025 Free PMC article.
-
Evidence for a predisposing background for CAG expansion leading to HTT mutation in a Chinese population.J Neurol Sci. 2010 Nov 15;298(1-2):57-60. doi: 10.1016/j.jns.2010.08.024. J Neurol Sci. 2010. PMID: 20864123
-
Personalized gene silencing therapeutics for Huntington disease.Clin Genet. 2014 Jul;86(1):29-36. doi: 10.1111/cge.12385. Epub 2014 Apr 11. Clin Genet. 2014. PMID: 24646433 Review.
-
Predictive testing for Huntington disease: interpretation and significance of intermediate alleles.Clin Genet. 2006 Oct;70(4):283-94. doi: 10.1111/j.1399-0004.2006.00668.x. Clin Genet. 2006. PMID: 16965319 Review.
Cited by
-
Therapeutic approaches to preventing cell death in Huntington disease.Prog Neurobiol. 2012 Dec;99(3):262-80. doi: 10.1016/j.pneurobio.2012.08.004. Epub 2012 Aug 28. Prog Neurobiol. 2012. PMID: 22967354 Free PMC article. Review.
-
A fully humanized transgenic mouse model of Huntington disease.Hum Mol Genet. 2013 Jan 1;22(1):18-34. doi: 10.1093/hmg/dds397. Epub 2012 Sep 21. Hum Mol Genet. 2013. PMID: 23001568 Free PMC article.
-
A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.Am J Hum Genet. 2019 Dec 5;105(6):1112-1125. doi: 10.1016/j.ajhg.2019.10.011. Epub 2019 Nov 7. Am J Hum Genet. 2019. PMID: 31708117 Free PMC article.
-
Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts.Cell Transplant. 2016;25(4):677-86. doi: 10.3727/096368916X690863. Epub 2016 Feb 4. Cell Transplant. 2016. PMID: 26850319 Free PMC article.
-
Is TGF-β1 a Biomarker of Huntington's Disease Progression?J Clin Med. 2021 Jul 5;10(13):3001. doi: 10.3390/jcm10133001. J Clin Med. 2021. PMID: 34279486 Free PMC article.
References
-
- Kremer B., Goldberg P., Andrew S.E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 1994;330:1401–1406. - PubMed
-
- Walker F.O. Huntington's disease. Lancet. 2007;369:218–228. - PubMed
-
- Telenius H., Kremer H.P., Theilmann J., Andrew S.E., Almqvist E., Anvret M., Greenberg C., Greenberg J., Lucotte G., Squitieri F. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum. Mol. Genet. 1993;2:1535–1540. - PubMed
-
- Almqvist E.W., Elterman D.S., MacLeod P.M., Hayden M.R. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin. Genet. 2001;60:198–205. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources